Neuropeptide Y receptor antagonists

Bibliography

• TATEMOTO K, CARLQUIST M, MUTT V: A novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature (1982) 296:659–660.
   PubMed Web of Science ®Google Scholar
• HIPSKIND PA, GEHLERT DR: Neuropeptide Y: at the dawn of subtype selective antagonists. Ann. Rep. Med. Chem. (1996) 31:1–10.
   Google Scholar
• WAHLESTEDT C, REISS D: Neuropeptide Y-related pep-tides and their receptors? Ann. Rev. Pharmacol. Toxicol (1993) 33:309–352.
   PubMedGoogle Scholar
• O'DONOHUE TL, VHRONWALL BM, PRUSS RM et al.: Neu-ropeptide Y and peptide YY neuronal and endocrine systems. Peptides (1985) 6:755–768.
   Google Scholar
• TATEMOTO K, MANN MJ, SHIMIZU M: Synthesis of re-ceptor antagonists of neuropeptide Y. Proc. Natl. Acad. ScL USA (1992) 89:1174–1178.
   PubMedGoogle Scholar
• MARTEL JC, FOURNIER A, ST PIERRE S, QUIRION R: Quan-titative autoradiographic distribution of [1251] Bolton-Hunter neuropeptide Y receptor binding sites in rat brain. Comparison with [1251] peptide YY receptor sites. Neuroscience (1990) 36:255–283.
   Google Scholar
• STANLEY BG, LEIBOWITZ SF: Neuropeptide Y injected in the paraventricular hypothalamus: a powerful stimulant of feeding behavior. Proc. Natl. Acad. ScL USA (1985) 82:3940–3943.
   PubMed Web of Science ®Google Scholar
• BECK B, STRICKER-KRONGRAD A, NICOLAS JP, BURLET C: Chronic and continuous intracerebroventricular in-fusion of neuropeptide Yin Long-Evans rats mimics of the feeding behavior of obese Zucker rats. Int. J. Obesity. (1991) 16:295–302.
   Google Scholar
• BOUBLIK JH, SCOTT NA, BROWN MR, RIVIER JE: Synthe-sis and hypertensive activity of neuropeptide Y frag-ments and analogues with modified N-or C-termini or D-substitutions. J. Med. Chem. (1989) 32:597–601.
   PubMedGoogle Scholar
• CHALMERS J, MORRIS M, KAPOOR V, CAIN M, ELLIOT J, RUSSEL A: Neuropeptide Y in the sympathetic control of blood pressure in hypertensive subjects. Chn. Exp. Hypertens. (1989) 1:59–66.
   Google Scholar
• KALRA SP, FUENTES M, FOURNIER A, PARKER SL,CROWLY WR: Involvement of the Y1 receptor subtype in the regulation of luteinizing hormone secretion by neuropeptide Y in rats. Endocrinology (1992) 130:3323–3330.
   PubMedGoogle Scholar
• WAHLESTEDT C, PICH EM, KOOB GF, YEE F, HEILIG M:Modulation of anxiety and neuropeptide Y-Y1 recep-tors by antisense aligodeoxynucleotides. Science (1993) 259:528–531.
   PubMed Web of Science ®Google Scholar
• THIELE TE, MARSH DJ, ST. MARIE L, BERNSTEIN IL, PALMI-TER RD: Ethanol consumption and resistance are in-versely related to neuropeptide Y levels. Nature (1998) 396:366–369.
   Google Scholar
• LARHAMMAR D, BLOMQVIST AG, YEE F, JAZIN E, Y00HY, WAHLESTEDT C: Cloning and functional expres-sion of a human neuropeptide Y peptide YY receptor of the Yl-type. J. Biol. Chem. (1992) 267:10935–10938.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ TW, FUHLENDORFF J, KJEMS LL, KRISTENSEN MS, VERVELDE M, O'HARE M: Signal epitopes in the three-dimensional structure of neuropeptide Y. Inter-action with Yl, Y2 and pancreatic polypeptide recep-tors. Ann. NY Acad. Sci. (1990) 611:209–214.
   Google Scholar
• WAHLESTEDT C, REGUNATHAN S, REIS DJ: Identifica-tion of cultured cells selectively expressing Y1-, Y2- or Y3-type receptors on neuropeptide Y/peptide YY. Life Sci. (1992) 50:7–12.
   PubMedGoogle Scholar
• MATTHEWS JE, JANSEN M, SLEPETIS RS, RASH VA, DAN-IELS AJ: Novel high affinity NPY antagonist identifies different subclasses of Y2-type NPY receptors. Soc. Neurosci. Abstr. (1995) 21(2):1593.
   Google Scholar
• ROSE PM, FERNANDES P, LYNCH JS, FRAZIER ST, FISHER SM, KODUKULA KK: Cloning and functional expression of a cDNA encoding a human Type 2 neuropeptide Y receptor. J. Biol. Chem. (1995) 270:22661–22664.
   PubMed Web of Science ®Google Scholar
• GERALD C, WALKER MW, VAYSEE PJ, HE CG, BRANCHEK TA, WEINSHANK RL: Pharmacological characterization of a human hippocampal neuropeptide Y peptide YY Y2 receptor subtype. J. Biol. Chem. (1995) 270:26758–26761.
   PubMed Web of Science ®Google Scholar
• GEHLERT DR: Subtypes of receptors for NPY: implica-tions for the targeting of therapeutics. Life Sci. (1994) 55:551–562.
   PubMed Web of Science ®Google Scholar
• LUNDELL I, BLOMQVIST AG, BERGLUND MM et al: Clon-ing of a human receptor of the NPY family with high affinity for pancreatic polypeptide and peptide YY. J. Biol. Chem. (1995) 270:29123–29128.
   PubMed Web of Science ®Google Scholar
• GERALD C, WALKER MW, CRISCIONE L et al.: A receptor subtype involved in neuropeptide-Y-induced food in-take. Nature (1996) 382:168–171.
   PubMed Web of Science ®Google Scholar
• HU Y, BLOOMQUIST BT, CORNFIELD LJ et al: Identifica-tion of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior. J. Biol. Chem. (1996) 271:26315–26319.
   PubMed Web of Science ®Google Scholar
• GEHLERT DR, HIPSLIND PA: Neuropeptide Y antago-nists: clinical promise and recent developments. Curr. Pharm. Des. (1995) 1:295–304.
   Google Scholar
• GRUNDEMAR L: Will neuropeptide Y receptor antago-nists offer new therapeutic approaches? Exp. Opin. Ther. Patents (1995) 5(10):1007.
   Google Scholar
• DOUGHTY MB, CHAURASIA CS, LI K: Benextramine-neuropeptide Y receptor interactions: contribution of the benzylic moieties to [311]neuropeptide Y displace-ment activity. J. Med. Chem. (1993) 36:272–279.
   PubMedGoogle Scholar
• DOUGHTY BM, CHU SS, MILLER DW, LI K, TESSEL RE: A long-lasting neuropeptide Y receptor antagonist. Eur. Pharmacol (1990) 296:659–660.
   Google Scholar
• CHAURASIA C, MISSE G, TESSEL R, DOUGHTY MB: Non-peptide peptidomimetic antagonists of the neuropep-tide Y receptor: benextramine analogues with selectivity for the peripheral Y2 receptor. J. Med. Chem. (1994) 37:2242–2248.
   PubMedGoogle Scholar
• KNIEPS S, MICHEL MC, DOVE S, BUSCHAUER A: Non-peptide neuropeptide Y antagonists derived from the histamine 112 agonist arpromidine: role of the gua-nidine group. Bioorg. Med. Chem. Lett. (1995) 5:2065–2070.
   Google Scholar
• HIPSKIND PA, LOBB KL, NIXON JA et al.: Potent and se-lective 1,2,3-trisubstituted indole NPY Y-1 antagonists. J. Med. Chem. (1997) 40:3712–3714.
   PubMed Web of Science ®Google Scholar
• DANIELS AJ, HEYER D, SPALTENSTEIN A: Peptide antago-nists of neuropeptide Y: design, structure and pharma-cological characterization. In: Neuropeptide Y and Drug Development. Grundemar L, Bloom, SR (Eds.), Academic Publishers, London, UK (1997):128–135.
   Google Scholar
• ZARRINMAYEH H, NUNES AM, ORNSTEIN PL et al.: Syn-thesis and evaluation of a series of novel 24(4-chlorophenoxy)methyll-benzimidazoles as selective neuropeptide Y Y1 receptor antagonists. J. Merl. Chem. (1998) 41:2709–2719.
   PubMed Web of Science ®Google Scholar
• WRIGHT J, BOLTON G, CRESWELL M, DOWNING D, GEORGIC L, HEFFNER T: 8-Amino-6-(aryl-sulfony0-5--nitroquinolines: novel nonpeptide neuropeptide Y1 receptor antagonists. Bioorg. Merl. Chem. Lett. (1996) 6:1809.
   Web of Science ®Google Scholar
• GAL CS, VALETTE G, ROUBY PE, PELLET A, OURY-DONATF, BROSSARD G: SR120819A, an orally-active and selec-tive neuropeptide Y Y1 receptor antagonist. FEBS Lett. (1995) 362:192–196.
   PubMedGoogle Scholar
• RUDOLF K, EBERLEIN W, ENGEL W, WIELAND HA, WIL-LIM KD, ENTZEROTH M: The first highly potent and se-lective non-peptide neuropeptide Y Y1 receptor antagonist: BIB3226. Eur. J. Pharmacol. (1994) 271:R11–R13.
   Google Scholar
• KORDIK CP, REITS AB: Pharmacological treatment ofobesity: therapeutic strategies. J. Med. Chem. (1999) 42:181–201.
   PubMed Web of Science ®Google Scholar